Bullish Reversal Built-Up
Diupdate
Sanofi shares have been plummeting because of lowering net income, disappointing return on equity and performance in the stock itself.
However, market was overreacting and short-term bullish reversal ought to be considered.
However, market was overreacting and short-term bullish reversal ought to be considered.
Catatan
No development for this stock, bottom appears to be built but there might be no rise in the share price unless market triggers a clear bullish impulse upwards. And the market is now choppy … I’ll be waiting for some good company news that may persuade people to invest in this stock.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.